TEVA Reminder Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Teva Pharmaceutical Industries Ltd.

BENSALEM, Pa.--()--Law Offices of Howard G. Smith reminds investors of the October 23, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”) (NYSE: TEVA) securities between November 15, 2016 and August 2, 2017, inclusive (the “Class Period”). Teva investors have until October 23, 2017 to file a lead plaintiff motion.

Investors suffering losses on their Teva investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

On August 2, 2016, Teva finalized its acquisition of Allergan plc’s generics business, Actavis Generis. Thereafter, Teva continued to make positive statements concerning the integration of the business, growth on intangible assets and goodwill, and general benefits of the acquisition. However, on August 3, 2017, Teva lowered its outlook and recorded a $6.1 billion impairment charge.

On this news, Teva’s stock price fell $7.50 per share, or 24%, to close at $23.75 on August 3, 2017, thereby injuring investors.

The complaint filed in this class action alleges that throughout the class period the Company issued materially false and/or misleading statements and/or failed to disclose adverse information concerning the Company’s business and outlook. Specifically, the complaint alleges that Teva failed to disclose the negative impact that the acquisition and integration of Actavis Generics was having on the Company’s financial results and business prospects.

If you purchased shares of Teva during the Class Period you may move the Court no later than October 23, 2017 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Recent Stories

RSS feed for Law Offices of Howard G. Smith

Release Summary

The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Teva Pharmaceutical Industries Ltd.(TEVA)

Law Offices of Howard G. Smith